Clinical Trials Browser

Recruiting × Fallopian Tube Neoplasms × Bevacizumab × Clear all

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06824467 2026-03-13

TroFuse-022

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07024784 2026-03-04

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasms

NCT05579366 2026-03-03

RAINFOL-01

Phase 1/2 Recruiting

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05739981 2026-02-27

MRD

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06890338 2026-02-24

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Phase 2 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT05445778 2026-02-23

GLORIOSA

Phase 3 Recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06469281 2026-02-03

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Phase 1 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06906341 2025-10-22

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Phase 2 Recruiting

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04919629 2025-05-11

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04516447 2024-11-26

A Study of ZN-c3 in Patients With Ovarian Cancer

Phase 1 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms